JP2005511612A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511612A5
JP2005511612A5 JP2003542191A JP2003542191A JP2005511612A5 JP 2005511612 A5 JP2005511612 A5 JP 2005511612A5 JP 2003542191 A JP2003542191 A JP 2003542191A JP 2003542191 A JP2003542191 A JP 2003542191A JP 2005511612 A5 JP2005511612 A5 JP 2005511612A5
Authority
JP
Japan
Prior art keywords
valaciclovir hydrochloride
anhydrous
anhydrous crystalline
spectrometer
resolution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003542191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511612A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/033926 external-priority patent/WO2003040145A1/en
Publication of JP2005511612A publication Critical patent/JP2005511612A/ja
Publication of JP2005511612A5 publication Critical patent/JP2005511612A5/ja
Pending legal-status Critical Current

Links

JP2003542191A 2001-11-05 2002-10-23 塩酸バラシクロビルの無水結晶形 Pending JP2005511612A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33331301P 2001-11-05 2001-11-05
PCT/US2002/033926 WO2003040145A1 (en) 2001-11-05 2002-10-23 Anhydrous crystal form of valaciclovir hydrochloride

Publications (2)

Publication Number Publication Date
JP2005511612A JP2005511612A (ja) 2005-04-28
JP2005511612A5 true JP2005511612A5 (enExample) 2005-12-22

Family

ID=23302261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003542191A Pending JP2005511612A (ja) 2001-11-05 2002-10-23 塩酸バラシクロビルの無水結晶形

Country Status (10)

Country Link
US (2) US20040197396A1 (enExample)
EP (1) EP1453834A1 (enExample)
JP (1) JP2005511612A (enExample)
AU (1) AU2002348022B2 (enExample)
CA (1) CA2465420A1 (enExample)
FR (1) FR2831885A1 (enExample)
GB (1) GB2383038B (enExample)
GR (1) GR1004358B (enExample)
IT (1) ITRM20020555A1 (enExample)
WO (1) WO2003040145A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374179A1 (en) * 2001-09-07 2005-10-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ グループ リミテッド 塩酸バラシクロビルの無水結晶形
US6849737B2 (en) * 2001-11-14 2005-02-01 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CN105753868B (zh) * 2016-04-12 2017-08-01 浙江理工大学 一种盐酸伐昔洛韦的半水合物及其制备方法
CN112176011B (zh) * 2020-10-26 2022-10-18 辰欣药业股份有限公司 一种酶催化制备盐酸伐昔洛韦的方法
CN116754538B (zh) * 2023-06-15 2024-05-07 深圳市新阳唯康科技有限公司 一种阿昔洛韦软膏的晶型定量方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
PL374179A1 (en) * 2001-09-07 2005-10-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ グループ リミテッド 塩酸バラシクロビルの無水結晶形
US6849737B2 (en) * 2001-11-14 2005-02-01 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
ES2270172T3 (es) * 2002-10-16 2007-04-01 Teva Pharmaceutical Industries Ltd. Procedimiento para reducir alcoholes residuales en hidrocloruro de valaciclovir cristalino.
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
US20050192296A1 (en) * 2004-01-21 2005-09-01 Zvi Harel Process for the preparation of valacyclovir hydrochloride
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Similar Documents

Publication Publication Date Title
JP2005511612A5 (enExample)
JP2023145481A5 (enExample)
JP2024001023A5 (enExample)
JP2018024682A5 (enExample)
GEP20105086B (en) Potassium salt of an hiv integrase inhibitor
JP2014524442A5 (enExample)
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
JP2007532560A5 (enExample)
JP2010506932A5 (enExample)
RU2598606C3 (ru) Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она
HRP20241443T1 (hr) Kristalni oblici 7-klor-2-(4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamida
IL167168A (en) Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria
JP2022037040A5 (enExample)
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
JPH1053576A5 (enExample)
FI3694863T3 (fi) Lorlatinibin vapaan emäksen hydraatin kidemuoto
CA2632283A1 (en) Polymorphs of a c-met/hgfr inhibitor
CY1107913T1 (el) Πολυμορφικες και αλλες κρυσταλλικες μορφες cis-ftc
RU2003118411A (ru) Кристаллические производные 1-метилкарбапенема
JP2005523933A5 (enExample)
JP2006249089A5 (enExample)
JP2021517111A5 (enExample)
JP2002308895A5 (enExample)
DE60043095D1 (de) Dampfspaltungskatalysator und dessen Herstellungsverfahren
ATE304014T1 (de) Neue kristalline form eines pyrrolidylthiocarbapenem-derivates